MERCURI-2

Phase 1

• Conditions: AKI; Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]

• Registration Number: CTIS2024-515260-31-00
• Lead Sponsor: Stichting Amsterdam UMC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-11
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 784

Inclusion Criteria

> 18 years-old, Undergoing elective cardiac surgery with cardio-pulmonary bypass (CPB) or off-pump coronary artery bypass surgery (OPCAB)., Providing informed consent

Exclusion Criteria

Current treatment with SGLT2 inhibitors, Reduced kidney function at baseline with eGFR < 20 ml/min at time of inclusion, Diabetes Mellitus Type 1, History of diabetic keto acidosis, Diabetes Mellitus Type 2 with BMI<25 for people with type 2 diabetes who are using multiple daily insulin injections (both short and long-acting insulin), Systolic blood pressure < 100 mmHg at time of inclusion, Emergency surgery, defined as in need of surgery for medical reasons < 7 days, i.e. S1- 4” according to the Amsterdam UMC classification, Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods, Known or suspected allergy to trial products or other drugs in the same class

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified